CDR 304
Alternative Names: CDR-304Latest Information Update: 06 Aug 2024
At a glance
- Originator CDR-Life
- Class Antibodies; Antineoplastics; Immunoglobulin Fv fragments; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 06 Aug 2024 Preclinical trials in Solid tumours in Switzerland (Parenteral) (CDR life pipeline, August 2024)
- 30 Jan 2023 Early research in Solid tumours in Switzerland (Parenteral) (CDR Life pipeline, January 2023)